IOVANCE BIOTHERAPEUTICS INC (1IOVA.MI) Stock Fundamental Analysis
Europe - Euronext Milan - BIT:1IOVA - US4622601007 - Common Stock
2.323 EUR
+0.02 (+1%)
1IOVA gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 83 industry peers in the Biotechnology industry. While 1IOVA seems to be doing ok healthwise, there are quite some concerns on its profitability. 1IOVA is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year 1IOVA has reported negative net income.
1IOVA had a negative operating cash flow in the past year.
In the past 5 years 1IOVA always reported negative net income.
1IOVA had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
1IOVA has a Return On Assets (-43.94%) which is in line with its industry peers.
Looking at the Return On Equity, with a value of -56.62%, 1IOVA is in line with its industry, outperforming 57.83% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -43.94% | ||
| ROE | -56.62% | ||
| ROIC | N/A |
ROA(3y)-52.47%
ROA(5y)-47.04%
ROE(3y)-69.19%
ROE(5y)-60.44%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
1IOVA has a Gross Margin (23.96%) which is in line with its industry peers.
1IOVA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 23.96% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
1IOVA does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, 1IOVA has more shares outstanding
Compared to 5 years ago, 1IOVA has more shares outstanding
The debt/assets ratio for 1IOVA has been reduced compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of -1.77, we must say that 1IOVA is in the distress zone and has some risk of bankruptcy.
1IOVA has a Altman-Z score of -1.77. This is in the lower half of the industry: 1IOVA underperforms 63.86% of its industry peers.
1IOVA has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.00, 1IOVA belongs to the top of the industry, outperforming 92.77% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.77 |
ROIC/WACCN/A
WACC8.82%
2.3 Liquidity
A Current Ratio of 3.41 indicates that 1IOVA has no problem at all paying its short term obligations.
With a decent Current ratio value of 3.41, 1IOVA is doing good in the industry, outperforming 68.67% of the companies in the same industry.
1IOVA has a Quick Ratio of 3.00. This indicates that 1IOVA is financially healthy and has no problem in meeting its short term obligations.
1IOVA has a Quick ratio of 3.00. This is in the better half of the industry: 1IOVA outperforms 68.67% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.41 | ||
| Quick Ratio | 3 |
3. Growth
3.1 Past
1IOVA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 20.13%, which is quite impressive.
The Revenue has grown by 175.62% in the past year. This is a very strong growth!
EPS 1Y (TTM)20.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%14.29%
Revenue 1Y (TTM)175.62%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%15.2%
3.2 Future
1IOVA is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 19.02% yearly.
Based on estimates for the next years, 1IOVA will show a very strong growth in Revenue. The Revenue will grow by 42.83% on average per year.
EPS Next Y17%
EPS Next 2Y24.23%
EPS Next 3Y22.59%
EPS Next 5Y19.02%
Revenue Next Year58.86%
Revenue Next 2Y59.19%
Revenue Next 3Y56.7%
Revenue Next 5Y42.83%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
1IOVA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for 1IOVA. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
1IOVA's earnings are expected to grow with 22.59% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.23%
EPS Next 3Y22.59%
5. Dividend
5.1 Amount
1IOVA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
BIT:1IOVA (12/29/2025, 7:00:00 PM)
2.323
+0.02 (+1%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners54.61%
Inst Owner ChangeN/A
Ins Owners0.32%
Ins Owner ChangeN/A
Market Cap922.16M
Revenue(TTM)250.43M
Net Income(TTM)-397.63M
Analysts75.56
Price Target7.3 (214.25%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2.45%
Min EPS beat(2)-13.7%
Max EPS beat(2)8.8%
EPS beat(4)2
Avg EPS beat(4)-11.94%
Min EPS beat(4)-47.45%
Max EPS beat(4)8.8%
EPS beat(8)5
Avg EPS beat(8)-4.19%
EPS beat(12)9
Avg EPS beat(12)3.75%
EPS beat(16)11
Avg EPS beat(16)2.89%
Revenue beat(2)0
Avg Revenue beat(2)-12.22%
Min Revenue beat(2)-15.78%
Max Revenue beat(2)-8.66%
Revenue beat(4)0
Avg Revenue beat(4)-16.36%
Min Revenue beat(4)-40.82%
Max Revenue beat(4)-0.2%
Revenue beat(8)2
Avg Revenue beat(8)-20.87%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)13.38%
PT rev (3m)N/A
EPS NQ rev (1m)6.87%
EPS NQ rev (3m)29.03%
EPS NY rev (1m)7.58%
EPS NY rev (3m)6.61%
Revenue NQ rev (1m)-1.68%
Revenue NQ rev (3m)-14.76%
Revenue NY rev (1m)-2.69%
Revenue NY rev (3m)-13.88%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 4.33 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.54 | ||
| P/tB | 2.6 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.01
EYN/A
EPS(NY)-0.51
Fwd EYN/A
FCF(TTM)-0.75
FCFYN/A
OCF(TTM)-0.69
OCFYN/A
SpS0.54
BVpS1.51
TBVpS0.89
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -43.94% | ||
| ROE | -56.62% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 23.96% | ||
| FCFM | N/A |
ROA(3y)-52.47%
ROA(5y)-47.04%
ROE(3y)-69.19%
ROE(5y)-60.44%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.28
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 76.09% | ||
| Cap/Sales | 11.45% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.41 | ||
| Quick Ratio | 3 | ||
| Altman-Z | -1.77 |
F-Score4
WACC8.82%
ROIC/WACCN/A
Cap/Depr(3y)118.96%
Cap/Depr(5y)1133.86%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)20.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%14.29%
EPS Next Y17%
EPS Next 2Y24.23%
EPS Next 3Y22.59%
EPS Next 5Y19.02%
Revenue 1Y (TTM)175.62%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%15.2%
Revenue Next Year58.86%
Revenue Next 2Y59.19%
Revenue Next 3Y56.7%
Revenue Next 5Y42.83%
EBIT growth 1Y6.05%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year8.44%
EBIT Next 3Y17.19%
EBIT Next 5YN/A
FCF growth 1Y6.75%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y9.11%
OCF growth 3YN/A
OCF growth 5YN/A
IOVANCE BIOTHERAPEUTICS INC / 1IOVA.MI FAQ
Can you provide the ChartMill fundamental rating for IOVANCE BIOTHERAPEUTICS INC?
ChartMill assigns a fundamental rating of 2 / 10 to 1IOVA.MI.
What is the valuation status of IOVANCE BIOTHERAPEUTICS INC (1IOVA.MI) stock?
ChartMill assigns a valuation rating of 1 / 10 to IOVANCE BIOTHERAPEUTICS INC (1IOVA.MI). This can be considered as Overvalued.
Can you provide the profitability details for IOVANCE BIOTHERAPEUTICS INC?
IOVANCE BIOTHERAPEUTICS INC (1IOVA.MI) has a profitability rating of 1 / 10.